Drug Patent List
Oppositions
Newsletter
Weekly Digest

Pharsight

Ponatinib Hydrochloride Patent Expiration

Ponatinib Hydrochloride is used for treating various types of leukemia, including acute lymphoblastic leukemia, chronic myeloid leukemia, and Philadelphia chromosome-positive acute lymphoblastic leukemia. It was first introduced by Takeda Pharmaceuticals Usa Inc in its drug Iclusig on Dec 14, 2012. 2 different companies have introduced drugs containing Ponatinib Hydrochloride.


Ponatinib Hydrochloride Patents

Given below is the list of patents protecting Ponatinib Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Iclusig US11192895 Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt Dec 12, 2033 Takeda Pharms Usa
Iclusig US11192897 Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt Dec 12, 2033 Takeda Pharms Usa
Iclusig US11384086 Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1- yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt Dec 12, 2033 Takeda Pharms Usa
Iclusig US8114874 Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors Jan 24, 2027 Takeda Pharms Usa
Iclusig US9029533 Substituted acetylenic imidazo[1,2-A]pyridazines as kinase inhibitors Dec 22, 2026 Takeda Pharms Usa
Iclusig US9493470 Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt Dec 12, 2033 Takeda Pharms Usa


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳

Ponatinib Hydrochloride Generics

Several generic applications have been filed for Ponatinib Hydrochloride.

Given below is the list of companies who have filed for Ponatinib Hydrochloride generic.


1. APOTEX

Apotex Inc has filed for 2 different strengths of generic version for Ponatinib Hydrochloride. Given below are the details of the strengths of this generic introduced by Apotex.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 15MG BASE tablet Discontinued ORAL N/A Jul 14, 2023
EQ 45MG BASE tablet Discontinued ORAL N/A Jul 14, 2023